Logo image of NXO.CA

NEXOPTIC TECHNOLOGY CORP (NXO.CA) Stock Fundamental Analysis

Canada - TSX-V:NXO - CA65341P1053 - Common Stock

0.01 CAD
0 (-33.33%)
Last: 7/15/2025, 7:00:00 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to NXO. NXO was compared to 13 industry peers in the Electronic Equipment, Instruments & Components industry. Both the profitability and financial health of NXO have multiple concerns. NXO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year NXO has reported negative net income.
In the past year NXO has reported a negative cash flow from operations.
NXO had negative earnings in each of the past 5 years.
In the past 5 years NXO always reported negative operating cash flow.
NXO.CA Yearly Net Income VS EBIT VS OCF VS FCFNXO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of NXO (-505.57%) is worse than 93.33% of its industry peers.
Industry RankSector Rank
ROA -505.57%
ROE N/A
ROIC N/A
ROA(3y)-921.95%
ROA(5y)-4359.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NXO.CA Yearly ROA, ROE, ROICNXO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5K -5K -10K -15K

1.3 Margins

NXO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NXO.CA Yearly Profit, Operating, Gross MarginsNXO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, NXO has more shares outstanding
Compared to 5 years ago, NXO has more shares outstanding
Compared to 1 year ago, NXO has a worse debt to assets ratio.
NXO.CA Yearly Shares OutstandingNXO.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
NXO.CA Yearly Total Debt VS Total AssetsNXO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

NXO has an Altman-Z score of -1602.31. This is a bad value and indicates that NXO is not financially healthy and even has some risk of bankruptcy.
NXO has a Altman-Z score of -1602.31. This is amonst the worse of the industry: NXO underperforms 93.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1602.31
ROIC/WACCN/A
WACCN/A
NXO.CA Yearly LT Debt VS Equity VS FCFNXO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M

2.3 Liquidity

NXO has a Current Ratio of 0.04. This is a bad value and indicates that NXO is not financially healthy enough and could expect problems in meeting its short term obligations.
NXO has a worse Current ratio (0.04) than 93.33% of its industry peers.
NXO has a Quick Ratio of 0.04. This is a bad value and indicates that NXO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NXO (0.04) is worse than 93.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.04
NXO.CA Yearly Current Assets VS Current LiabilitesNXO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

1

3. Growth

3.1 Past

NXO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.30%, which is quite impressive.
EPS 1Y (TTM)88.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
NXO.CA Price Earnings VS Forward Price EarningsNXO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXO.CA Per share dataNXO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0 -0 -0.01 -0.01 -0.01

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

NXO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NEXOPTIC TECHNOLOGY CORP

TSX-V:NXO (7/15/2025, 7:00:00 PM)

0.01

0 (-33.33%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)07-23 2025-07-23
Earnings (Next)08-27 2025-08-27
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners8.61%
Ins Owner ChangeN/A
Market Cap1.95M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -505.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-921.95%
ROA(5y)-4359.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.04
Quick Ratio 0.04
Altman-Z -1602.31
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y79.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y97.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.77%
OCF growth 3YN/A
OCF growth 5YN/A